Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9000708rdf:typepubmed:Citationlld:pubmed
pubmed-article:9000708lifeskim:mentionsumls-concept:C0011882lld:lifeskim
pubmed-article:9000708lifeskim:mentionsumls-concept:C0021547lld:lifeskim
pubmed-article:9000708lifeskim:mentionsumls-concept:C2348609lld:lifeskim
pubmed-article:9000708lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:9000708pubmed:issue2lld:pubmed
pubmed-article:9000708pubmed:dateCreated1997-2-12lld:pubmed
pubmed-article:9000708pubmed:abstractTextNerve myo-inositol depletion, which has been implicated in the pathogenesis of acute experimental diabetic neuropathy, can be reproduced in normal rats by feeding diets enriched in L-fucose, a competitive inhibitor of sodium-dependent myo-inositol transport. Previously, we reported that L-fucose feeding for 6 weeks reproduces the effect of experimental diabetes on nerve Na+-K+-ATPase activity and conduction velocity, which can be prevented by simultaneous dietary myo-inositol supplementation. To further validate this model of myo-inositol depletion, we examined the effects of long-term (24-week) L-fucose feeding and dietary myo-inositol supplementation on nerve Na+-K+-ATPase, nerve conduction velocity, and myelinated nerve fiber pathology. After 24 weeks of L-fucose enriched (10 or 20%) diets, nerve myo-inositol levels and Na+-K+-ATPase activity decreased significantly (P < 0.05) and were associated with a 25-30% reduction in nerve conduction velocity, all of which were completely prevented by 1% dietary myo-inositol. Twenty percent L-fucose diet resulted in significant axonal atrophy, paranodal swelling (P < 0.001), and paranodal demyelination (P < 0.005), without increasing Wallerian degeneration or nerve fiber loss, a pattern qualitatively similar to that seen in early murine diabetic neuropathy. Dietary myo-inositol supplementation prevented these structural changes and increased nodal remyelination, supporting a role of myo-inositol depletion in the genesis of early diabetic neuropathy. The L-fucose model system may therefore serve as an experimental tool to elucidate the pathophysiological role of isolated myo-inositol depletion and its consequences in the multifactorial pathogenesis of diabetic neuropathy.lld:pubmed
pubmed-article:9000708pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:languageenglld:pubmed
pubmed-article:9000708pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9000708pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9000708pubmed:statusMEDLINElld:pubmed
pubmed-article:9000708pubmed:monthFeblld:pubmed
pubmed-article:9000708pubmed:issn0012-1797lld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:GreeneD ADAlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:SimaA AAAlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:DunlapJ AJAlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:YorekM AMAlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:DavidsonE PEPlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:WieseT JTJlld:pubmed
pubmed-article:9000708pubmed:authorpubmed-author:LightleR LRLlld:pubmed
pubmed-article:9000708pubmed:issnTypePrintlld:pubmed
pubmed-article:9000708pubmed:volume46lld:pubmed
pubmed-article:9000708pubmed:ownerNLMlld:pubmed
pubmed-article:9000708pubmed:authorsCompleteYlld:pubmed
pubmed-article:9000708pubmed:pagination301-6lld:pubmed
pubmed-article:9000708pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:meshHeadingpubmed-meshheading:9000708-...lld:pubmed
pubmed-article:9000708pubmed:year1997lld:pubmed
pubmed-article:9000708pubmed:articleTitleSupplemental myo-inositol prevents L-fucose-induced diabetic neuropathy.lld:pubmed
pubmed-article:9000708pubmed:affiliationDepartment of Pathology, Wayne State University, Detroit, Michigan 48236, USA.lld:pubmed
pubmed-article:9000708pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9000708pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9000708pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9000708lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9000708lld:pubmed